115 related articles for article (PubMed ID: 20608842)
1. In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.
Reddy VB; Doss GA; Karanam BV; Samuel K; Lanza TJ; Lin LS; Yu NX; Zhang AS; Raab CE; Stearns RA; Kumar S
Xenobiotica; 2010 Sep; 40(9):650-62. PubMed ID: 20608842
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Karanam B; Addy C; Bateman T; Reddy VB; Li S; Dean D; Li H; Jones A; Schenk D; Zhang AS; Braun M; Freeman A; Flach S; Stoch A; Chodakewitz J; Wagner JA; Kumar S
Xenobiotica; 2010 Oct; 40(10):691-700. PubMed ID: 20722472
[TBL] [Abstract][Full Text] [Related]
3. Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Lin LS; Ha S; Ball RG; Tsou NN; Castonguay LA; Doss GA; Fong TM; Shen CP; Xiao JC; Goulet MT; Hagmann WK
J Med Chem; 2008 Apr; 51(7):2108-14. PubMed ID: 18333607
[TBL] [Abstract][Full Text] [Related]
4. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Du W; Jewell JP; Lin LS; Colandrea VJ; Xiao JC; Lao J; Shen CP; Bateman TJ; Reddy VB; Ha SN; Shah SK; Fong TM; Hale JJ; Hagmann WK
Bioorg Med Chem Lett; 2009 Sep; 19(17):5195-9. PubMed ID: 19632830
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
[TBL] [Abstract][Full Text] [Related]
9. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats.
Johnson KA; Prakash C
Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349
[TBL] [Abstract][Full Text] [Related]
10. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
Fichna J; Sibaev A; Sałaga M; Sobczak M; Storr M
Neurogastroenterol Motil; 2013 Aug; 25(8):e550-9. PubMed ID: 23692073
[TBL] [Abstract][Full Text] [Related]
12. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
Prakash C; Wang W; O'Connell T; Johnson KA
Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases.
Karanam BV; Hop CE; Liu DQ; Wallace M; Dean D; Satoh H; Komuro M; Awano K; Vincent SH
Drug Metab Dispos; 2004 Sep; 32(9):1015-22. PubMed ID: 15319344
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
[TBL] [Abstract][Full Text] [Related]
15. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Hagmann WK
Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes.
Uchiyama M; Koda H; Fischer T; Mueller J; Yamamura N; Oguchi M; Iwabuchi H; Okazaki O; Izumi T
Drug Metab Dispos; 2011 Jul; 39(7):1311-9. PubMed ID: 21511943
[TBL] [Abstract][Full Text] [Related]
17. Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.
Kochansky CJ; Xia YQ; Wang S; Cato B; Creighton M; Vincent SH; Franklin RB; Reed JR
Drug Metab Dispos; 2005 Dec; 33(12):1894-904. PubMed ID: 16183782
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
Dean BJ; Chang S; Silva Elipe MV; Xia YQ; Braun M; Soli E; Zhao Y; Franklin RB; Karanam B
Drug Metab Dispos; 2007 Feb; 35(2):283-92. PubMed ID: 17132765
[TBL] [Abstract][Full Text] [Related]
19. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
[TBL] [Abstract][Full Text] [Related]
20. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
